Hubertus von Baumbach, EFPIA president (Credit: EFPIA via YouTube)

Eu­ro­pean phar­ma group wants to cre­ate PRV-like sys­tem to spur an­tibi­otics R&D

New re­search fund­ed by a Eu­ro­pean phar­ma in­dus­try group is look­ing to rein­vig­o­rate an­timi­cro­bial R&D with a sys­tem that’s sim­i­lar to the pri­or­i­ty re­view vouch­er sys­tems in the US, which spurs new re­search in rare pe­di­atric dis­eases, rare trop­i­cal dis­eases and med­ical coun­ter­mea­sures.

As the need for nov­el an­tibi­otics is ur­gent, EF­PIA is call­ing for a Trans­fer­able Ex­clu­siv­i­ty Ex­ten­sion (TEE) vouch­er sys­tem where de­vel­op­ers of nov­el an­tibi­otics can win a vouch­er that can then be used to ex­tend the ex­clu­siv­i­ty of an­oth­er drug for a pe­ri­od of time, or sold to an­oth­er com­pa­ny, there­by pay­ing for the an­tibi­ot­ic re­search.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.